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A B S T R A C T
Objective: To evaluate and compare the eﬀects of concomitant lamotrigine (LTG) or carbamazepine (CBZ) on the
incidence of treatment-emergent adverse events (TEAEs) in patients taking adjunctive eslicarbazepine acetate
(ESL) for focal (partial-onset) seizures (FS).
Methods: These post-hoc analyses of data pooled from three randomized, double-blind, placebo-controlled
studies of adjunctive ESL (BIA-2093-301, −302 and −304) included adults (≥16 years) with FS refractory to
1–3 antiepileptic drugs (AEDs). Patients were randomized equally to placebo, ESL 400mg (Studies 301 and 302
only), 800mg, or 1200mg once daily (8-week baseline, 2-week titration, and 12-week maintenance periods).
TEAEs, TEAEs leading to discontinuation, and serious AEs (SAEs) were evaluated in patients taking, or not
taking, LTG (excluding those taking CBZ or phenytoin [PHT]; i.e., the +LTG and −LTG/–CBZ subgroups), or
CBZ (excluding those taking LTG or PHT; i.e., the +CBZ and −LTG/–CBZ subgroups) at baseline.
Results: LTG was used concomitantly by 248 patients (+LTG; placebo, n=81; ESL, n=167) and CBZ by 613
patients (+CBZ; placebo, n=172; ESL, n=441); 361 patients were taking neither LTG nor CBZ (−LTG/–CBZ;
placebo, n=109; ESL, n=252). The overall incidence of TEAEs with ESL (any dose) was numerically higher for
+CBZ (77%) than for +LTG (73%) or –LTG/–CBZ (68%; statistical signiﬁcance not tested). Among patients
taking ESL, dizziness, diplopia, and vomiting were reported more frequently in the +CBZ subgroup (30%, 14%,
and 10%, respectively) than in the +LTG (16%, 8%, 5%) or –LTG/–CBZ (11%, 3%, 5%) subgroups. The overall
incidence of TEAEs leading to discontinuation with ESL was higher for +CBZ (21%) than for +LTG (13%) or
–LTG/–CBZ (15%). Dizziness leading to discontinuation with ESL was reported more frequently in the +CBZ
subgroup than in the +LTG or –LTG/–CBZ subgroups (9%, 3%, and 3%, respectively). The overall incidence of
SAEs in patients taking ESL was comparable across subgroups (+LTG, 5%; +CBZ, 6%; –LTG/–CBZ, 5%). The
results were similar when evaluating placebo-adjusted incidences.
Conclusion: There was a potential pharmacodynamic interaction between AEDs with a putatively similar me-
chanism of action, with a seemingly lesser interaction between ESL and LTG versus ESL and CBZ. If combining
ESL with LTG or CBZ, clinicians should be aware of the potential risk for an increased incidence of TEAEs
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typically associated with voltage-gated sodium channel inhibitors (e.g., dizziness, blurred vision, vertigo, di-
plopia, headache, or vomiting).
1. Introduction
Eslicarbazepine acetate (ESL) is a once-daily (QD) oral antiepileptic
drug (AED) for the treatment of focal (partial-onset) seizures (FS) as
either monotherapy or adjunctive therapy in patients aged ≥4 years.
When AEDs are used as adjunctive therapy, potential drug interactions
are a concern, including both pharmacokinetic and pharmacodynamic
interactions.
Speciﬁc combinations of AEDs may increase the frequency of some
adverse events (AEs) (Abou-Khalil, 2016; French and Gazzola, 2013).
Pharmacodynamic interactions may be of particular importance when
combining agents thought to have similar mechanisms of action (MoA).
Such interactions have been demonstrated with combinations of two
AEDs acting predominantly on voltage-gated sodium channels (VGSCs),
such as carbamazepine (CBZ), phenytoin (PHT), oxcarbazepine (OXC),
lamotrigine (LTG), and lacosamide (LCM) (Barcs et al., 2000; Besag
et al., 1998; Sake et al., 2010). Eslicarbazepine (the primary metabolite
of ESL) is also known to inhibit VGSCs, which may contribute to its
anticonvulsant eﬀect (Bonifacio et al., 2001). A pharmacodynamic in-
teraction between ESL and CBZ leading to higher incidences of dizzi-
ness and diplopia has been previously suggested (Biton et al., 2017);
however, other VGSC inhibitors were not excluded from this previous
analysis. The eﬀect of concomitant LTG on the tolerability proﬁle of ESL
is not known.
We therefore performed an exploratory post-hoc analysis of data
pooled from three Phase III studies of ESL to evaluate the impact of
concomitant LTG use on the incidence of AEs during adjunctive ESL
treatment. The impact of concomitant CBZ use was also evaluated and
compared with the impact of LTG. We did not conduct a similar analysis
for PHT, as relatively few patients (∼9%) were taking PHT at baseline.
2. Methods
Data were pooled from three randomized, placebo-controlled,
double-blind trials, as reported previously (Biton et al., 2017). The
three Phase III studies (BIA-2093-301 [NCT00957684], −302
[NCT00957047], and −304 [NCT00988429] (Ben-Menachem et al.,
2010; Elger et al., 2009; Sperling et al., 2015); registered at
ClinicalTrials.gov) were performed in accordance with the principles of
the Declaration of Helsinki, the International Conference on Harmoni-
sation guidelines, and relevant national, state, and local laws. Study
protocols were approved by the relevant independent ethics commit-
tees/institutional review boards, and all patients provided written in-
formed consent.
2.1. Study design
The individual study designs, including details of randomization
and blinding, have been reported previously (Ben-Menachem et al.,
2010; Elger et al., 2009; Sperling et al., 2015). Brieﬂy, each study
comprised an 8-week baseline period, a 2-week titration period, and a
12-week maintenance period (Fig. 1). After the baseline period, eligible
patients were randomized equally to receive ESL 400mg QD (Studies
301 and 302 only), 800mg QD, 1200mg QD, or placebo. Patients
continued to receive stable doses of baseline AEDs throughout the
studies. On completion of the 12-week maintenance period, patients
entered an ESL taper period (Studies 301 and 304) and exited the study
(Fig. 1). The ESL titration and tapering-oﬀ schedules diﬀered slightly
between studies.
2.2. Patients
Eligible patients were aged ≥16 years (Study 304) or ≥18 years
(Studies 301 and 302) and taking 1–3 AEDs at baseline. In addition,
patients had ≥4 FS in either the ﬁrst or last 4 weeks of the baseline
period plus no seizure-free period> 21 consecutive days (Studies 301
and 302), or≥8 FS during baseline (with≥3 seizures in either the ﬁrst
or last 4 weeks) and no seizure-free period> 28 consecutive days
(Study 304). Inclusion and exclusion criteria have been reported pre-
viously (Ben-Menachem et al., 2010; Elger et al., 2009; Sperling et al.,
2015). Of note, patients taking OXC were excluded from study parti-
cipation.
2.3. Safety assessments
The safety population comprised all patients who received≥1 dose
of study drug. AEs were considered treatment-emergent (TEAEs) if they
began after the ﬁrst dose of study drug (or if unknown/unclear, after
randomization). AEs were recorded and assessed by the investigators
and coded using the Medical Dictionary for Regulatory Activities ver-
sion 13.1. Additional events were detected from audits of investigator
records and case report forms, and from review of patient narratives
Fig. 1. Design of the Phase III studies.
ESL, eslicarbazepine acetate; QD, once daily;
TC, telephone contact. aTitration schedules
diﬀered between Studies 301, 302, and 304.
bStudies 301 and 302 only. cPatients who did
not enter the open-label extension study dis-
continued ESL (Studies 301 and 304: 2-week
down-titration; Study 302: abrupt discontinua-
tion).
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and serious AE (SAE) reports. Signs and symptoms relating to any re-
ported diagnoses were recorded as additional TEAEs. Safety endpoints
included: overall incidence of TEAEs, TEAEs leading to discontinuation,
SAEs, and deaths.
2.4. Statistical analysis
To minimize the potential confounding eﬀect of other putative
VGSC inhibitors, patients taking CBZ or PHT at baseline were excluded
in the +/–LTG subgroup analyses; similarly, patients taking LTG or
PHT at baseline were excluded in the +/–CBZ subgroup analyses.
Three patient subgroups were compared descriptively: 1) +LTG sub-
group: patients taking LTG without CBZ or PHT; 2) +CBZ subgroup:
patients taking CBZ without LTG or PHT; 3) –LTG/–CBZ subgroup:
patients not taking LTG, CBZ, or PHT.
Demographic and baseline characteristics, and patient disposition
were summarized descriptively for each subgroup (+LTG, +CBZ,
–LTG/–CBZ). The numbers and percentages of patients with TEAEs,
TEAEs leading to discontinuation, and SAEs were reported. Placebo-
adjusted incidences of TEAEs and TEAEs leading to discontinuation
were calculated as [incidence with ESL] – [incidence with placebo].
The statistical signiﬁcance of the TEAE incidence diﬀerence be-
tween the +LTG and –LTG/–CBZ subgroups, as well as between the
+CBZ and –LTG/–CBZ subgroups, was examined by calculating p va-
lues, using the chi-square test of independence, or Fisher’s exact test
(for TEAEs with low incidence, i.e., occurring in ﬁve patients or fewer);
corrections for multiplicity were not applied. The signiﬁcance threshold
was preset at p < 0.05.
3. Results
3.1. Patients
The safety population comprised 1447 patients (placebo: n=426;
ESL 400mg: n=196; ESL 800mg: n=415; ESL 1200mg: n=410).
There were 248 patients in the +LTG subgroup (placebo: n=81; ESL:
n=167), 613 patients in the +CBZ subgroup (placebo: n= 172; ESL: n
= 441), and 361 patients in the –LTG/–CBZ subgroup (placebo:
n=109; ESL: n=252).
Baseline demographic and clinical characteristics are presented in
Supplemental Table 1, according to subgroup. A greater proportion of
patients taking ESL (any dose) were taking two or more AEDs at
baseline in the +LTG subgroup (81%) than in the +CBZ (67%) or
–LTG/–CBZ (62%) subgroups. A greater proportion of patients taking
ESL were receiving CBZ as a monotherapy at baseline (33%) than were
receiving LTG as a monotherapy (19%). Baseline use of valproic acid
(VPA; 17%, 12%, and 52%) and levetiracetam (LEV; 25%, 9%, 34%)
was less frequent in the +LTG and +CBZ subgroups than in the –LTG/
–CBZ subgroup. Other baseline demographic and clinical characteristics
were similar across subgroups.
Patient disposition is summarized in Table 1, according to subgroup.
The proportion of patients that discontinued due to AEs was generally
higher with higher ESL doses. A greater proportion of patients taking
ESL (any dose) withdrew due to AEs in the +CBZ subgroup (16%) than
in the +LTG (10%) or –LTG/–CBZ (10%) subgroups.
3.2. Overall incidence of TEAEs
The incidences of TEAEs in the patient population pooled from
Studies 301, 302, and 304 have been reported previously (Biton et al.,
2017). The overall incidences of TEAEs with placebo were comparable
across the +LTG, +CBZ, and –LTG/–CBZ subgroups (57%, 59%, and
58%, respectively; Table 2). The overall incidence of TEAEs with ESL
(any dose) was numerically higher for +CBZ (77%) than for +LTG
(72%) or –LTG/–CBZ (68%) (Table 2); the overall placebo-adjusted
incidences of TEAEs were 18%, 16%, and 10%, respectively (Fig. 2,
Supplemental Table 2). The overall incidence of TEAEs appeared to be
related to ESL dose in the +LTG and –LTG/–CBZ subgroups, but not in
the +CBZ subgroup (Table 2). Among patients taking the highest ESL
dose evaluated (1200mg QD), the overall incidence of TEAEs was
Table 1
Patient disposition.
n (%) –LTG/–CBZ +LTG +CBZ
ESL, mg QD ESL, mg QD ESL, mg QD
Placebo 400 800 1200 Total Placebo 400 800 1200 Total Placebo 400 800 1200 Total
n=109 n=37 n=116 n=99 n=252 n=81 n=32 n=64 n=71 n=167 n=172 n=99 n=174 n=168 n=441
Completed the study 94 (86) 34 (92) 99 (85) 74 (75) 207 (82) 70 (86) 28 (88) 55 (86) 54 (76) 137 (82) 144 (84) 90 (91) 135 (78) 108 (64) 333 (76)
Discontinued during:
16-week double-
blind period
15 (14) 3 (8) 17 (15) 25 (25) 45 (18) 11 (14) 4 (13) 9 (14) 17 (24) 30 (18) 28 (16) 9 (9) 39 (22) 60 (36) 108 (24)
Titration period 2 (2) 0 5 (4) 11 (11) 16 (6) 5 (6) 2 (6) 4 (6) 6 (8) 12 (7) 6 (3) 1 (1) 15 (9) 16 (10) 32 (7)
Maintenance
period
12 (11) 2 (5) 12 (10) 14 (14) 28 (11) 6 (7) 2 (6) 5 (8) 11 (15) 18 (11) 19 (11) 8 (8) 24 (14) 42 (25) 74 (17)
Taper period 1 (1) 1 (3) 0 0 1 (< 1) 0 0 0 0 0 3 (2) 0 0 2 (1) 2 (< 1)
Main reason for discontinuation (double-blind period)
AEs 4 (4) 2 (5) 9 (8) 15 (15) 26 (10) 1 (1) 3 (9) 2 (3) 12 (17) 17 (10) 7 (4) 7 (7) 24 (14) 40 (24) 71 (16)
Withdrawal of
consent
3 (3) 1 (3) 2 (2) 6 (6) 9 (4) 4 (5) 1 (3) 4 (6) 3 (4) 8 (5) 8 (5) 2 (2) 5 (3) 9 (5) 16 (4)
Compliance issues 3 (3) 0 1 (1) 0 1 (< 1) 1 (1) 0 0 0 0 4 (2) 0 0 4 (2) 4 (1)
Protocol violation 0 0 1 (1) 2 (2) 3 (1) 1 (1) 0 1 (2) 0 1 (1) 2 (1) 0 2 (1) 1 (1) 3 (1)
Exacerbation of
seizures
0 0 0 0 0 0 0 0 1 (1) 1 (1) 1 (1) 0 0 0 0
Pregnancy 2 (2) 0 0 0 0 0 0 0 0 0 0 0 1 (1) 0 1 (< 1)
Administrative
reasons
1 (1) 0 1 (1) 1 (1) 2 (1) 1 (1) 0 1 (2) 0 1 (1) 0 0 2 (1) 2 (1) 4 (1)
Other 2 (2) 0 3 (3) 1 (1) 4 (2) 3 (4) 0 1 (2) 1 (1) 2 (1) 5 (3) 0 5 (3) 2 (1) 7 (2)
AE, adverse event; CBZ, carbamazepine; +CBZ, patients who were taking CBZ at baseline; –CBZ, patients who were not taking CBZ at baseline; ESL, eslicarbazepine
acetate; LTG, lamotrigine; +LTG, patients who were taking LTG at baseline; –LTG, patients who were not taking LTG at baseline; QD, once daily.
Data are for patients who received≥1 dose of study drug (safety population) and who were not taking phenytoin, CBZ (+LTG and –LTG/–CBZ subgroups only), or
LTG (+CBZ and –LTG/–CBZ subgroups only) at baseline. Data were rounded to the nearest whole percent.
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numerically higher for +LTG (82%, n=58/71) than for +CBZ (78%,
n=131/168) or –LTG/–CBZ (75%, n=74/99; Table 2); overall pla-
cebo-adjusted incidences of TEAEs with ESL 1200mg QD were 25%,
19%, and 17%, respectively (see Supplemental Table 2).
3.3. Individual TEAE incidences
Table 2 shows the most frequently reported TEAEs with ESL, de-
ﬁned as an incidence of ≥5% in the total ESL group in any of the
+LTG, +CBZ, or –LTG/–CBZ subgroups. These were somnolence,
nausea, dizziness, rash, vomiting, diplopia, headache, blurred vision,
fatigue, vertigo, and ataxia, with the majority reported more frequently
with higher ESL doses in all subgroups.
When all ESL doses were combined, the incidences of the most
common TEAEs were similar between the +LTG and –LTG/–CBZ sub-
groups (Table 2). The exceptions were dizziness, blurred vision, rash,
and vertigo, with a diﬀerence of≥5% between subgroups for dizziness.
The incidence of dizziness was 16% for +LTG versus 11% for –LTG/
–CBZ (p=0.1334; Table 2). The placebo-adjusted incidence of vertigo
was 6% for +LTG versus 1% for –LTG/–CBZ (Fig. 2, Supplemental
Table 2).
When all ESL doses were combined, the most common TEAEs were
generally more frequent in the +CBZ subgroup than in the –LTG/–CBZ
subgroup, with ≥5% diﬀerence between subgroups for dizziness (30%
vs. 11%, p<0.0001), diplopia (14% vs. 3%, p<0.0001), vomiting
(10% vs. 5%, p = 0.0264), ataxia (7% vs. 2%, p = 0.0059), and
headache (18% vs. 11%, p = 0.0141) (Table 2). Placebo-adjusted in-
cidences of dizziness were 19% and 5% and of diplopia were 11% and
Table 2
TEAE incidences,a according to use of LTG or CBZ at baseline.
–LTG/–CBZ +LTG +CBZ
ESL, mg QD ESL, mg QD ESL, mg QD
n (%) Placebo 400 800 1200 Total Placebo 400 800 1200 Total Placebo 400 800 1200 Total
n=109 n=37 n=116 n=99 n=252 n=81 n=32 n=64 n=71 n=167 n=172 n=99 n=174 n=168 n=441
Any TEAEb 63 (58) 19 (51) 79 (68) 74 (75) 172 (68) 46 (57) 19 (59) 44 (69) 58 (82) 121 (72) 101 (59) 75 (76) 133 (76) 131 (78) 339 (77)
Somnolence 6 (6) 8 (22) 12 (10) 21 (21) 41 (16) 7 (9) 3 (9) 7 (11) 15 (21) 25 (15) 19 (11) 12 (12) 23 (13) 25 (15) 60 (14)
Nausea 5 (5) 2 (5) 11 (9) 11 (11) 24 (10) 4 (5) 2 (6) 3 (5) 9 (13) 14 (8) 12 (7) 9 (9) 21 (12) 29 (17) 59 (13)
Dizziness 7 (6) 2 (5) 12 (10) 14 (14) 28 (11) 7 (9) 3 (9) 9 (14) 15 (21) 27 (16) 18 (10) 21 (21) 48 (28) 62 (37) 131 (30)
Rash 2 (2) 1 (3) 5 (4) 8 (8) 14 (6) 0 0 0 2 (3) 2 (1) 2 (1) 0 0 2 (1) 2 (< 1)
Vomiting 2 (2) 1 (3) 4 (3) 8 (8) 13 (5) 3 (4) 2 (6) 1 (2) 5 (7) 8 (5) 6 (3) 4 (4) 19 (11) 21 (13) 44 (10)
Diplopia 0 0 5 (4) 3 (3) 8 (3) 4 (5) 2 (6) 3 (5) 8 (11) 13 (8) 5 (3) 9 (9) 24 (14) 28 (17) 61 (14)
Headache 9 (8) 2 (5) 13 (11) 13 (13) 28 (11) 5 (6) 4 (13) 5 (8) 8 (11) 17 (10) 21 (12) 15 (15) 32 (18) 33 (20) 80 (18)
Blurred vision 0 0 2 (2) 3 (3) 5 (2) 2 (2) 2 (6) 4 (6) 3 (4) 9 (5) 1 (1) 7 (7) 12 (7) 8 (5) 27 (6)
Fatigue 4 (4) 0 5 (4) 9 (9) 14 (6) 4 (5) 3 (9) 7 (11) 5 (7) 15 (9) 4 (2) 3 (3) 4 (2) 12 (7) 19 (4)
Vertigo 1 (1) 0 2 (2) 3 (3) 5 (2) 0 2 (6) 1 (2) 7 (10) 10 (6) 1 (1) 4 (4) 4 (2) 11 (7) 19 (4)
Ataxia 1 (1) 0 2 (2) 3 (3) 5 (2) 2 (2) 2 (6) 1 (2) 3 (4) 6 (4) 5 (3) 4 (4) 12 (7) 13 (8) 29 (7)
CBZ, carbamazepine; +CBZ, patients who were taking CBZ at baseline; –CBZ, patients who were not taking CBZ at baseline; ESL, eslicarbazepine acetate; LTG,
lamotrigine; +LTG, patients who were taking LTG at baseline; –LTG, patients who were not taking LTG at baseline; QD, once daily; TEAE, treatment-emergent
adverse event.
Data are for patients who received≥1 dose of study drug (safety population) and who were not taking phenytoin, CBZ (+LTG and –LTG/–CBZ subgroups only), or
LTG (+CBZ and –LTG/–CBZ subgroups only) at baseline.
Data were rounded to the nearest whole percent.
a For TEAEs with an incidence ≥5% (for all ESL doses combined) in either the –LTG/–CBZ, +LTG, or +CBZ subgroup.
b Patients with more than one event were only counted once.
Fig. 2. Placebo-adjusted TEAE incidences,a ac-
cording to use of LTG or CBZ at baseline.
CBZ, carbamazepine; +CBZ, patients who were
taking CBZ at baseline; –CBZ, patients who
were not taking CBZ at baseline; ESL, esli-
carbazepine acetate; LTG, lamotrigine; +LTG,
patients who were taking LTG at baseline;
–LTG, patients who were not taking LTG at
baseline; TEAE, treatment-emergent adverse
event.
aIn the total ESL group, for TEAEs with an in-
cidence ≥5% (for all ESL doses combined) in
either the –LTG/–CBZ, +LTG, or +CBZ sub-
group.
bPatients with more than one event were only
counted once.
Data were rounded to the nearest whole per-
cent.
Data are for patients who received ≥1 dose of
study drug (safety population) and who were
not taking phenytoin, CBZ (+LTG and –LTG/
–CBZ subgroups only), or LTG (+CBZ and
–LTG/–CBZ subgroups only) at baseline. Placebo-adjusted incidences of TEAEs were calculated as [incidence with ESL] – [incidence with placebo]. Negative
incidences are not shown.
Black boxes highlight TEAEs for which the diﬀerence in placebo-adjusted incidence between +CBZ and –LTG/–CBZ was≥5% higher than between +LTG and –LTG/
–CBZ.
B. Abou-Khalil et al. Epilepsy Research 147 (2018) 80–86
83
3% for +CBZ versus –LTG/–CBZ, respectively (Fig. 2, Supplemental
Table 2).
At the highest ESL dose (1200mg QD), incidences of some TEAEs
appeared to be higher for +LTG than for –LTG/–CBZ, but the diﬀer-
ences between subgroups were not statistically signiﬁcant (dizziness:
+LTG 21%, –LTG/–CBZ 14%, p = 0.232; diplopia: +LTG 11%, –LTG/
–CBZ 3%, p= 0.054; vertigo: +LTG 10%, –LTG/–CBZ 3%, p= 0.096).
Incidences of some TEAEs also appeared to be higher for +CBZ than for
–LTG/–CBZ in the ESL 1200 mg dose group, with dizziness and diplopia
statistically signiﬁcantly more frequent in the +CBZ subgroup than in
the –LTG/–CBZ subgroup (nausea: +CBZ 17%, –LTG/–CBZ 11%, p =
0.174; dizziness: +CBZ 37%, –LTG/–CBZ 14%, p = 0.0001; vomiting:
+CBZ 13%, –LTG/–CBZ 8%, p = 0.262; diplopia: +CBZ 17%, –LTG/
–CBZ 3%, p = 0.0006; headache: +CBZ 20%, –LTG/–CBZ 13%, p =
0.174).
When all ESL doses were combined, the diﬀerence in placebo-ad-
justed incidence between +CBZ and –LTG/–CBZ was higher than be-
tween +LTG and –LTG/–CBZ with a ≥5% diﬀerence for dizziness,
diplopia, and vomiting (diﬀerence between +CBZ and –LTG/–CBZ vs.
diﬀerence between +LTG and –LTG/–CBZ: 14% vs. 3%, 8% vs. 0%, and
4% vs. −2%, respectively; Fig. 2, Supplemental Table 2). This pattern
was also apparent in the ESL 800mg QD (13% vs. 1%, 7% vs.−4%, 5%
vs.−4%) and ESL 1200mg QD (18% vs. 6%, 11% vs. 3%, 3% vs.−3%)
dose groups. No other TEAEs were consistently more frequent with
concomitant CBZ or LTG across ESL dose groups.
The incidence of the investigator-reported TEAE of hyponatremia
was low and similar across subgroups for all ESL doses combined
(–LTG/–CBZ 1.6%, +LTG 2.4%, +CBZ 1.1%), with the majority of
events occurring at the 800mg and 1200mg QD doses.
3.4. Discontinuations, SAEs, and deaths
The overall incidence of TEAEs leading to discontinuation with ESL
(any dose) was higher for +CBZ (21%) than for +LTG (13%) or –LTG/
–CBZ (15%) (Table 3); placebo-adjusted overall incidences were 13%,
8%, and 6%, respectively. Dizziness (the most frequently reported TEAE
leading to discontinuation) was reported more frequently in the +CBZ
subgroup than in the +LTG or –LTG/–CBZ subgroups (9%, 3%, and 3%,
respectively; Table 3); the placebo-adjusted incidences of dizziness
leading to discontinuation were 7%, 3%, and 3%, respectively. In the
+CBZ subgroup, the incidence of dizziness leading to discontinuation
appeared to be ESL dose-dependent. The overall incidence of SAEs in
patients taking ESL (any dose) was comparable across subgroups
(+LTG, 5%; +CBZ, 6%; –LTG/–CBZ, 5%; Supplemental Table 3).
There was one death in the –LTG/–CBZ subgroup, due to decreased
body temperature (hypothermia); the patient was in the placebo group.
Two deaths were reported in the +CBZ subgroup; one in the placebo
group (due to pneumonia, septic shock, acute respiratory failure, and
decreased oxygen saturation), and one in the ESL 800mg QD dose
group, due to status epilepticus. No deaths were reported in the +LTG
subgroup.
4. Discussion
The current analysis suggests possible pharmacodynamic interac-
tions between ESL and both LTG and CBZ. However, the extent of the
interaction between ESL and LTG may be lesser than that between ESL
and CBZ, despite the fact that both AEDs are thought to act pre-
dominantly via a similar MoA (VGSC inhibition).
When treating patients with combinations of AEDs, clinicians
should take into account all potential interactions (both pharmacoki-
netic and pharmacodynamic) between the AEDs in the combination.
The concomitant use of AEDs with similar MoAs has been reported to
lead to AEs at therapeutic doses/serum concentrations. For example, in
a large study of adults with a recent diagnosis of FS, who were taking
two diﬀerent AEDs concomitantly, combinations of AEDs with a similar
MoA were associated with shorter persistence and greater risk of dis-
continuation compared with AED combinations with diﬀerent MoAs
(Margolis et al., 2014). Increased incidences of dizziness, ataxia, and
diplopia have been previously reported during use of speciﬁc combi-
nations of VGSC inhibitors. The use of CBZ plus LTG has been linked to
diplopia and dizziness (Besag et al., 1998). In another study, the in-
cidence of dizziness was considerably higher when LCM was combined
with another VGSC inhibitor, versus an AED with a diﬀerent MoA (Sake
et al., 2010). A similar pattern of increased AEs was noted when ESL
was combined with CBZ versus other AEDs both in the current analysis,
and in Biton et al. (2017). However, in the current analysis, the inter-
action between ESL and LTG appeared to have a somewhat lesser
Table 3
Incidences of individual TEAEs leading to discontinuation,a according to use of LTG or CBZ at baseline.
–LTG/–CBZ +LTG +CBZ
ESL, mg QD ESL, mg QD ESL, mg QD
n (%) Placebo 400 800 1200 Total Placebo 400 800 1200 Total Placebo 400 800 1200 Total
n=109 n=37 n=116 n=99 n=252 n=81 n=32 n=64 n=71 n=167 n=172 n=99 n=174 n=168 n=441
Any TEAE leading to
discontinuationb
9 (8) 4 (11) 12 (10) 21 (21) 37 (15) 4 (5) 4 (13) 4 (6) 14 (20) 22 (13) 14 (8) 10 (10) 33 (19) 48 (29) 91 (21)
Dizziness 0 0 5 (4) 3 (3) 8 (3) 0 0 0 5 (7) 5 (3) 2 (1) 2 (2) 15 (9) 21 (13) 38 (9)
Nausea 1 (1) 0 2 (2) 4 (4) 6 (2) 0 1 (3) 0 4 (6) 5 (3) 0 0 6 (3) 12 (7) 18 (4)
Diplopia 0 0 1 (1) 0 1 (< 1) 0 1 (3) 1 (2) 0 2 (1) 0 2 (2) 5 (3) 9 (5) 16 (4)
Vomiting 1 (1) 0 0 4 (4) 4 (2) 0 1 (3) 0 3 (4) 4 (2) 1 (1) 2 (2) 8 (5) 10 (6) 20 (5)
Ataxia 0 0 0 1 (1) 1 (< 1) 0 2 (6) 0 2 (3) 4 (2) 0 2 (2) 6 (3) 8 (5) 16 (4)
Vertigo 0 0 0 1 (1) 1 (< 1) 0 1 (3) 1 (2) 2 (3) 4 (2) 1 (1) 0 0 2 (1) 2 (< 1)
Somnolence 1 (1) 0 0 5 (5) 5 (2) 0 1 (3) 0 1 (1) 1 (1) 1 (1) 0 5 (3) 5 (3) 10 (2)
Rash 0 0 1 (1) 4 (4) 5 (2) 0 0 0 1 (1) 1 (1) 0 0 0 1 (1) 1 (< 1)
Gait disturbance 0 0 1 (1) 0 1 (< 1) 0 2 (6) 1 (2) 1 (1) 4 (2) 0 0 1 (1) 0 1 (< 1)
CBZ, carbamazepine; +CBZ, patients who were taking CBZ at baseline; –CBZ, patients who were not taking CBZ at baseline; ESL, eslicarbazepine acetate; LTG,
lamotrigine; +LTG, patients who were taking LTG at baseline; –LTG, patients who were not taking LTG at baseline; QD, once daily; TEAE, treatment-emergent
adverse event.
Data are for patients who received≥1 dose of study drug (safety population) and who were not taking phenytoin, CBZ (+LTG and –LTG/–CBZ subgroups only), or
LTG (+CBZ and –LTG/–CBZ subgroups only) at baseline.
Data were rounded to the nearest whole percent.
a For TEAEs leading to discontinuation with an incidence ≥2% (for all ESL doses combined) in either the –LTG/–CBZ, +LTG, or +CBZ subgroup.
b Patients with more than one event were only counted once.
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impact on the frequency and severity of some TEAEs than the interac-
tion between ESL and CBZ.
The overall incidence of TEAEs with ESL (any dose) was numerically
higher for +CBZ than for +LTG or –LTG/–CBZ; the relatively higher
TEAE incidence in the +CBZ subgroup appeared to be primarily driven
by dizziness, diplopia, and vomiting, of which incidences appeared to
be ESL dose-dependent. At the highest ESL dose evaluated (1200mg
QD), the overall incidence of TEAEs was numerically higher for +LTG
than for +CBZ or –LTG/–CBZ. This may indicate a pharmacodynamic
interaction between ESL and LTG, but primarily at the highest ESL dose
evaluated. It is possible that a potential interaction between ESL and
LTG would have been most marked at higher doses or serum con-
centrations of LTG; however, we were unable to investigate the impact
of LTG dose/serum concentration, as these data were unavailable.
Similarly, the impact of CBZ dose/serum concentration could not be
evaluated.
As would be expected, in the absence of other VGSC inhibitors (i.e.,
in the –LTG/–CBZ subgroup), incidences of speciﬁc TEAEs typically
associated with use of VGSC inhibitors appeared to occur more fre-
quently with higher ESL doses. Incidences of individual TEAEs were
generally comparable between the +LTG and –LTG/–CBZ subgroups
when all ESL doses were combined. However, at the highest ESL dose
(1200mg QD), incidences of dizziness, diplopia, and vertigo were
higher in patients taking LTG than in those who were not (though none
of the diﬀerences between subgroups were statistically signiﬁcant).
Dizziness, diplopia, and headache occurred more frequently in the
+CBZ subgroup than in the –LTG/–CBZ subgroup. In addition, nausea,
dizziness, vomiting, diplopia, and headache were more frequent in the
+CBZ subgroup than in the –LTG/–CBZ subgroup in the ESL 1200mg
dose group; the diﬀerences between subgroups were statistically sig-
niﬁcant for dizziness and diplopia. Our ﬁndings extend those reported
by Biton et al. (2017), who completed a similar analysis of LTG using
this dataset, but without excluding patients taking other putative VGSC
inhibitors (i.e., LTG and PHT). In combination, these data suggest po-
tential pharmacodynamic interactions between ESL and LTG, and ESL
and CBZ, possibly due to the shared putative MoA of these AEDs (VGSC
inhibition). Incidence diﬀerences between the +CBZ and –LTG/–CBZ
subgroups were higher than between the +LTG and –LTG/–CBZ sub-
groups for dizziness, diplopia, and vomiting, across ESL doses, poten-
tially suggesting diﬀerences in tolerability between these VGSC in-
hibitor combinations (CBZ and ESL vs. LTG and ESL).
The overall incidence of TEAEs leading to discontinuation (all ESL
doses combined) was higher for +CBZ than for +LTG and –LTG/–CBZ.
Discontinuations were most frequent at the highest ESL dose (1200mg
QD) in all subgroups, presumably due to the higher drug load. Dizziness
led to discontinuation more frequently in the +CBZ subgroup than in
the +LTG and –LTG/–CBZ subgroups, again suggesting potential tol-
erability diﬀerences between VGSC inhibitor combinations. The overall
incidences of SAEs (all ESL doses combined) were comparable across
subgroups.
One could speculate that the apparently diﬀering levels of phar-
macodynamic interaction between ESL and LTG versus ESL and CBZ
might relate to diﬀerences in MoAs of the drugs. VGSC inhibition is not
the sole MoA of LTG, which, unlike CBZ, may act on hyperpolarization-
activated cyclic nucleotide-gated channel currents (Grunze et al., 1998;
Zona et al., 2002), calcium channels (Dibue et al., 2013), and nicotinic
receptors (Valles et al., 2007; Zheng et al., 2010). VGSC-inhibiting
AEDs with multiple MoAs (including valproate and topiramate) do not
have the same pharmacodynamic interactions with ‘classic’ VGSC in-
hibitors as ‘classic’ VGSC inhibitors do with each other. We are also
unable to exclude the possibility that diﬀerences between subgroups
may have been partly related to average administered doses of CBZ and
LTG, as we do not know the doses or serum concentrations of these
AEDs for the majority of patients in the current studies.
It is of note that 81% of patients taking ESL in the +LTG subgroup
were receiving two or more baseline AEDs, compared with 67% in the
+CBZ subgroup, and 62% in the –LTG/–CBZ subgroup. Therefore, it is
also possible that patients in the +LTG subgroup were taking higher
doses of baseline AEDs than those in the +CBZ or –LTG/–CBZ sub-
groups, increasing the risk of AEs. These factors may have contributed
towards the higher apparent incidences of AEs in the +LTG subgroup,
compared with the –LTG/–CBZ subgroup, that would not have aﬀected
the +CBZ subgroup.
A limitation of the current analysis is the post-hoc nature of the
analyses. Statistical comparisons of TEAE incidences were carried out
retrospectively, and the majority of results were compared descriptively
between subgroups. Corrections for multiplicity were not applied to the
calculated p values; therefore, these values merely provide preliminary
information on the incidence diﬀerences between subgroups that could
potentially be examined further in the future. An additional limitation
was that the doses and serum concentrations of LTG and CBZ could not
be evaluated, such that possible dose/exposure diﬀerences between the
non-randomized +CBZ and +LTG subgroups could not be accounted
for. Nevertheless, our comparison of the ESL–LTG and ESL–CBZ com-
binations is strongly suggestive of diﬀerences that are relevant to
clinical practice.
5. Conclusion
Our results suggest a potential pharmacodynamic interaction be-
tween AEDs with a putatively similar MoA. However, the pharmaco-
dynamic interaction appeared to diﬀer somewhat between VGSC in-
hibitors, with a lesser interaction between ESL and LTG versus ESL and
CBZ. If combining LTG or CBZ with ESL, clinicians should be aware of
the potential risk for an increased incidence of TEAEs typically asso-
ciated with VGSC inhibitors (e.g., dizziness, blurred vision, vertigo,
diplopia, headache, or vomiting). One option for management of such
events could be to reduce the dose of either LTG or CBZ.
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